20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Beta Bionics, Inc. - (BBNX) operates in the NASDAQ industry and is headquartered in Irvine, United States with about 420 employees. Its market capitalization is roughly $821 million. In the fiscal year ended 2025-12-31, BBNX reported $100M in revenue and ($73M) in net income.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
Interactive charts & full statements → Open the BBNX valuation workbench →
| Income statement | TTM → 2026-09-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $128M | $100M | $65M | $12M | $0M |
| Gross Profit | $74M | $56M | $36M | $6M | $0M |
| Gross Margin % | 57.8% | 55.4% | 55.1% | 52.6% | 100.0% |
| Operating Income (EBIT) | ($93M) | ($72M) | ($45M) | ($36M) | ($66M) |
| Operating Margin % | -72.7% | -71.5% | -69.5% | -298.9% | -36784.4% |
| Net Income | ($82M) | ($73M) | ($55M) | ($44M) | ($65M) |
| Net Margin % | -64.1% | -73.0% | -84.1% | -367.6% | -36173.7% |
| EBITDA | — | ($70M) | ($54M) | ($43M) | ($63M) |
| Earnings Per Share (EPS) | $-1.87 | $-1.81 | $-1.28 | $-1.03 | $-1.51 |
| Shares Outstanding (M) | — | 41M | 43M | 43M | 43M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $36M | $32M | $28M | $32M | $27M | $23M | $18M | $20M | $17M |
| Gross Profit | $20M | $19M | $16M | $19M | $15M | $13M | $9M | $12M | $9M |
| Gross Margin % | 55.6% | 59.0% | 59.5% | 59.0% | 55.5% | 53.8% | 50.9% | 57.2% | 53.4% |
| Operating Income (EBIT) | ($27M) | ($26M) | ($24M) | ($16M) | ($17M) | ($20M) | ($19M) | ($13M) | ($11M) |
| Operating Margin % | -75.0% | -79.9% | -87.9% | -50.2% | -62.5% | -85.5% | -105.7% | -63.8% | -65.7% |
| Net Income | ($24M) | ($23M) | ($22M) | ($13M) | ($14M) | ($17M) | ($29M) | ($18M) | ($10M) |
| Net Margin % | -66.7% | -73.1% | -79.3% | -41.9% | -52.1% | -72.6% | -162.5% | -88.6% | -58.3% |
| EBITDA | — | ($24M) | ($21M) | ($13M) | ($14M) | ($16M) | ($28M) | ($18M) | ($9M) |
| Earnings Per Share (EPS) | $-0.52 | $-0.53 | $-0.49 | $-0.33 | $-0.33 | $-0.39 | $-0.66 | $-0.42 | $-0.23 |
| Shares Outstanding (M) | — | 45M | 44M | 41M | 44M | 43M | 43M | 43M | 43M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-09-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($60M) | ($51M) | ($48M) | ($32M) | ($60M) |
| Capital Expenditures (CapEx) | $6M | $5M | $3M | $0M | $1M |
| Free Cash Flow (FCF) | ($67M) | ($56M) | ($52M) | ($33M) | ($61M) |
| FCF Margin % | -52.3% | -56.1% | -79.3% | -273.8% | -34067.0% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($12M) | ($15M) | ($24M) | ($9M) | ($9M) | ($14M) | ($20M) | ($14M) | ($10M) |
| Capital Expenditures (CapEx) | $2M | $1M | $1M | $2M | $1M | $2M | $0M | $1M | $2M |
| Free Cash Flow (FCF) | ($15M) | ($16M) | ($25M) | ($11M) | ($10M) | ($15M) | ($20M) | ($15M) | ($12M) |
| FCF Margin % | -41.7% | -48.9% | -91.2% | -32.8% | -36.7% | -66.1% | -115.1% | -72.6% | -69.0% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-09-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets | $444M | $329M | $150M | $110M | $36M |
| Cash & Cash Equivalents | $82M | $32M | $30M | $27M | $28M |
| Total Liabilities | $42M | $41M | $74M | $51M | $206M |
| Total Debt (Short + Long-Term) | — | $2M | $2M | $1M | $1M |
| Total Shareholders' Equity | $401M | $288M | $76M | $59M | ($170M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BBNX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms